Brett A. Pletcher's Insider Trades & SAST Disclosures
Brett A. Pletcher's most recent trade in Cytokinetics Inc was a trade of 51,039 Non-Qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 30, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Brett A. Pletcher.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics Inc | Brett A. Pletcher | EVP, Chief Legal Officer | 30 Aug 2024 | 51,039 | 51,039 | - | - | Non-Qualified Stock Option (Right to Buy) | ||
| Cytokinetics Inc | Brett A. Pletcher | EVP, Chief Legal Officer | 30 Aug 2024 | 33,140 | 33,140 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 782 | 16,519 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2022 | 782 | 33,706 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.74 per share. | 10 Jun 2022 | 280 | 33,426 (0%) | 0% | 60.7 | 17,007 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Sale of securities on an exchange or to another person at price $ 58.24 per share. | 10 Mar 2022 | 3,634 | 32,576 (0%) | 0% | 58.2 | 211,644 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 3,130 | 17,301 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 3,130 | 38,299 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,593 | 20,431 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,593 | 35,169 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.92 per share. | 10 Mar 2022 | 2,089 | 36,210 (0%) | 0% | 57.9 | 120,995 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Grant, award, or other acquisition of securities at price $ 52.13 per share. | 15 Feb 2022 | 348 | 32,924 (0%) | 0% | 52.1 | 18,141 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Sale of securities on an exchange or to another person at price $ 63.89 per share. | 09 Feb 2022 | 1,691 | 32,576 (0%) | 0% | 63.9 | 108,038 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 2,727 | 23,024 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2022 | 2,727 | 35,303 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.90 per share. | 06 Feb 2022 | 1,036 | 34,267 (0%) | 0% | 63.9 | 66,200 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Sale of securities on an exchange or to another person at price $ 68.54 per share. | 01 Feb 2022 | 14,061 | 32,576 (0%) | 0% | 68.5 | 963,682 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Grant, award, or other acquisition of securities at price $ 55.09 per share. | 15 Aug 2021 | 32 | 29,198 (0%) | 0% | 55.1 | 1,763 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 72,855 | 72,855 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 12,520 | 25,751 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2021 | 2,593 | 31,759 (0%) | 0% | - | Common Stock | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2021 | 2,593 | 13,231 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Sale of securities on an exchange or to another person at price $ 63.36 per share. | 15 Feb 2021 | 1,486 | 29,166 (0%) | 0% | 63.4 | 94,153 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 63.91 per share. | 15 Feb 2021 | 1,107 | 30,652 (0%) | 0% | 63.9 | 70,748 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Grant, award, or other acquisition of securities at price $ 56.86 per share. | 15 Feb 2021 | 334 | 29,166 (0%) | 0% | 56.9 | 18,990 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Sale of securities on an exchange or to another person at price $ 67.41 per share. | 10 Feb 2021 | 1,975 | 28,832 (0%) | 0% | 67.4 | 133,135 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2021 | 2,728 | 31,560 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2021 | 2,728 | 15,824 | - | - | Restricted Stock Unit | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 68.46 per share. | 06 Feb 2021 | 753 | 30,807 (0%) | 0% | 68.5 | 51,550 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Sale of securities on an exchange or to another person at price $ 65.97 per share. | 01 Feb 2021 | 9,711 | 28,832 (0%) | 0% | 66.0 | 640,633 | Common Stock |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 14,188 | 28,832 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 13,447 | 42,279 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences, Inc. | Brett A. Pletcher | EVP,Corp Affairs & Gen Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.70 per share. | 26 Jan 2021 | 3,736 | 38,543 (0%) | 0% | 66.7 | 249,191 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges